Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study
Omalizumab is highly effective and safe in CIndU patients, with long estimated treatment duration mainly reflecting long disease duration. Our data show omalizumab's high potential as treatment in any subtype of CIndU and support its clinical use for these patients.
Authors
- Juul M. P. A. van den Reek (ORCID: https://orcid.org/0000-0002-3642-2673)
- Andaç Salman (ORCID: https://orcid.org/0000-0002-6407-926X)
- Michael Rudenko (ORCID: https://orcid.org/0000-0002-6065-9451)
- Bahar Sevimli Dikicier (ORCID: https://orcid.org/0000-0002-1912-3946)
- Simon Francis Thomsen (ORCID: https://orcid.org/0000-0002-4838-300X)
- Stamatios Gregoriou (ORCID: https://orcid.org/0000-0002-7585-1032)
- Heike Röckmann (ORCID: https://orcid.org/0000-0002-8565-2619)
- Roberta Fachini Jardim Criado (ORCID: https://orcid.org/0000-0003-2482-3047)
- Nasser Mohammad Porras
- Rabia Öztaş Kara (ORCID: https://orcid.org/0000-0003-1828-5844)
- Jennifer Astrup Sørensen (ORCID: https://orcid.org/0009-0001-4243-9535)
- Lea Kiefer (ORCID: https://orcid.org/0000-0003-2882-4784)
- Shunsuke Takahagi (ORCID: https://orcid.org/0000-0001-9951-1342)
- Andreas Kleinheinz (ORCID: https://orcid.org/0000-0002-0379-4403)
- Ana Maria Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-5434-7753)
- Mehran Alizadeh Aghdam (ORCID: https://orcid.org/0000-0003-3584-9250)
- Yoshimi Matsuo
- André C. Knulst (ORCID: https://orcid.org/0000-0002-1056-3179)
- Karen A. Ritchie (ORCID: https://orcid.org/0000-0002-0688-8982)
- Martijn B. A. van Doorn (ORCID: https://orcid.org/0000-0003-1672-7899)
- Emek Kocatürk (ORCID: https://orcid.org/0000-0003-2801-0959)
- Marcus Maurer (ORCID: https://orcid.org/0000-0002-4121-481X)
- Reineke Soegiharto (ORCID: https://orcid.org/0000-0002-1942-2508)
- Fatih Demir (ORCID: https://orcid.org/0000-0002-8181-0739)
- Esmee van Lindonk
- Tatjana Bobylev
- Michihiro Hide
Institutions
- Sakarya University (TR)
- Hiroshima University (JP)
- University of Copenhagen (DK)
- Koç University (TR)
- Radboud University Nijmegen (NL)
- Universitat Pompeu Fabra (ES)
- National and Kapodistrian University of Athens (GR)
- Bispebjerg Hospital (DK)
- Erasmus MC (NL)
- Hospital Italiano de Buenos Aires (AR)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Humboldt-Universität zu Berlin (DE)
- Hiroshima City Asa Citizens Hospital (JP)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Andreas Sygros Hospital (GR)
- Centre for Human Drug Research (NL)
- Elbe Kliniken Stade-Buxtehude (DE)
- Faculdade de Medicina do ABC (BR)
- Kent Hastanesi (TR)
- Acıbadem Adana Hospital (TR)
- Marmara University (TR)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Allergy
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1111/all.16334
- Citations
- 14
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 6.58
Funders
- Novartis Pharma